PMC10415914_01
T1 sequences of contrast-enhanced MRI-scans of the brain; A: MRI at the time of presentation. A1: sagittal flair imaging. A2: sagittal T1 imaging with contrast agent. A3: coronal T1 imaging with contrast agent. B: MRI 4 weeks after treatment initiation. B1: sagittal flair imaging. B2: sagittal T1 imaging with contrast agent. B3: coronal T1 imaging with contrast agent. C: MRI 8 weeks after treatment initiation. C1: sagittal flair imaging. C2: sagittal T1 imaging with contrast agent. C3: coronal T1 imaging with contrast agent. D: MRI 12 weeks after treatment initiation. D1: sagittal flair imaging. D2: sagittal T1 imaging with contrast agent. D3: coronal T1 imaging with contrast agent. E: MRI 17 weeks after treatment initiation. E1: sagittal flair imaging. E2: sagittal T1 imaging with contrast agent. E3: coronal T1 imaging with contrast agent. F: MRI 30 weeks after treatment initiation. F1: sagittal flair imaging. F2: sagittal T1 imaging with contrast agent. F3: coronal T1 imaging with contrast agent.
gr1.jpg
PMC10415914_01_gr1.jpg
fig0005
Magnetic resonance imaging (MRI) of the brain showed signal enhancement in the left frontal lobe, extending to the corona radiata (Fig. 1A). After 5 weeks of treatment, repeated cerebral MRI showed equivocal results with on the one hand reduced contrast-enhancement, whereas the flair hyperintensity was progressive compared to the initial MRI scan (Fig. 1B). Follow-up cerebral MRI eight weeks after initiation of the anti-infective treatment revealed a regressive, but ongoing contrast-enhancement of the brain lesion (Fig. 1C). Afterwards, repeated cerebral MRI scans confirmed regression of the contrast-enhancing area and excluded further abscess formations (Fig. 1D).